Hunting for clinical translation with innate-like immune cells and their receptors

Leukemia

Volumn 28, Issue 6, 2014, Pages 1181-1190

  Scheper, W ^a   Grunder C ^a   Straetemans, T ^a   Sebestyen, Z ^a   Kuball, J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

allogeneic stem cell transplantation; hematological malignancies; innate like lymphocytes; natural killer cells; T cells

Indexed keywords

B7 ANTIGEN; CD16 ANTIGEN; CD19 ANTIGEN; CD3 ANTIGEN; CD56 ANTIGEN; CD86 ANTIGEN; GAMMA INTERFERON; HLA A ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; INTERLEUKIN 2; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 2; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; NATURAL KILLER CELL RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2D; CD1 ANTIGEN; CD94 ANTIGEN; ENDOTHELIAL PROTEIN C RECEPTOR; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NATURAL KILLER CELL RECEPTOR NKG2A; PROTEOHEPARAN SULFATE;

ANTINEOPLASTIC ACTIVITY; CELL POPULATION; CELL SURFACE; CYTOMEGALOVIRUS; CYTOTOXICITY; DENDRITIC CELL; GAMMA DELTA T LYMPHOCYTE; GRAFT VERSUS HOST REACTION; HAPLOTYPE; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOBIOLOGY; INNATE IMMUNITY; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR CELL; TUMOR IMMUNITY; VIRUS INFECTION; ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; ALLELE; ALLOGENEIC STEM CELL TRANSPLANTATION; ALLOIMMUNITY; ANTIGEN RECOGNITION; CANCER SURVIVAL; CROSS REACTION; CYTOKINE RELEASE; CYTOMEGALOVIRUS INFECTION; GENETIC POLYMORPHISM; IMMUNORECEPTOR TYROSINE BASED INHIBITION MOTIF; LEUKEMIA; RECURRENCE FREE SURVIVAL; SOLID TUMOR; T LYMPHOCYTE ACTIVATION;

ANTIGEN-PRESENTING CELLS; HUMANS; IMMUNITY, INNATE; NEOPLASMS; RECEPTORS, IMMUNOLOGIC;

EID: 84902112549     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.378     Document Type: Review

References (120)

1. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med 2006; 354: 1813-1826.
2. Bornhauser M, Thiede C, Babatz J, Schetelig J, Illmer T, Kiani A et al. Infusion of bcr/abl peptide-reactive donor T cells to achieve molecular remission of chronic myeloid leukemia after CD34+ selected allogeneic hematopoietic cell transplantation. Leukemia 2006; 20: 2055-2057. (Pubitemid 44614903)
3. Cobbold M, Khan N, Pourgheysari B, Tauro S, McDonald D, Osman H et al. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med 2005; 202: 379-386. (Pubitemid 41126955)
4. Meij P, Jedema I, Van Der Hoorn MA, Bongaerts R, Cox L, Wafelman AR et al. Generation and administration of HA-1-specific T-cell lines for the treatment of patients with relapsed leukemia after allogeneic stem cell transplantation: A pilot study. Haematologica 2012; 97: 1205-1208.
5. Van Driessche A, Gao L, Stauss HJ, Ponsaerts P, Van Bockstaele DR, Berneman ZN et al. Antigen-specific cellular immunotherapy of leukemia. Leukemia 2005; 19: 1863-1871. (Pubitemid 41553993)
6. Hayday AC. Gammadelta T cells and the lymphoid stress-surveillance response. Immunity 2009; 31: 184-196.
7. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL et al. Innate or adaptive immunity? The example of natural killer cells. Science 2011; 331: 44-49.
8. Baychelier F, Sennepin A, Ermonval M, Dorgham K, Debre P, Vieillard V. Identification of a cellular ligand for the natural cytotoxicity receptor NKp44. Blood 2013; 122: 2935-2942.
9. Delahaye NF, Rusakiewicz S, Martins I, Menard C, Roux S, Lyonnet L et al. Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med 2011; 17: 700-707.
10. Harly C, Guillaume Y, Nedellec S, Peigne CM, Monkkonen H, Monkkonen J et al. Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human gamma delta T-cell subset. Blood 2012; 120: 2269-2279.
11. Uldrich AP, Le NJ, Pellicci DG, Gherardin NA, McPherson KG, Lim RT et al. CD1d-lipid antigen recognition by the gamma delta TCR. Nat Immunol 2013; 14: 1137-1145.
12. Vavassori S, Kumar A, Wan GS, Ramanjaneyulu GS, Cavallari M, El DS et al. Butyrophilin 3A1 binds phosphorylated antigens and stimulates human gamma delta T cells. Nat Immunol 2013; 14: 908-916.
13. Scheper W, van DS, Kersting S, Pietersma F, Lindemans C, Hol S et al. Gamma deltaT cells elicited by CMV reactivation after allo-SCT cross-recognize CMV and leukemia. Leukemia 2013; 27: 1328-1338.
14. Willcox CR, Pitard V, Netzer S, Couzi L, Salim M, Silberzahn T et al. Cytomegalovirus and tumor stress surveillance by binding of a human gamma delta T cell antigen receptor to endothelial protein C receptor. Nat Immunol 2012; 13: 872-879.
15. Green ML, Leisenring WM, Xie H, Walter RB, Mielcarek M, Sandmaier BM et al. CMV reactivation after allogeneic HCT and relapse risk: Evidence for early protection in acute myeloid leukemia. Blood 2013; 122: 1316-1324.
16. Ito S, Pophali P, Co W, Koklanaris EK, Superata J, Fahle GA et al. CMV reactivation is associated with a lower incidence of relapse after allo-SCT for CML. Bone Marrow Transplant 2013; 48: 1313-1316.
17. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol 2001; 22: 633-640. (Pubitemid 33043908)
18. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999; 285: 727-729.
19. Cosman D, Mullberg J, Sutherland CL, Chin W, Armitage R, Fanslow W et al. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 2001; 14: 123-133. (Pubitemid 32206515)
20. Marcu-Malina V, Heijhuurs S, van Buuren M, Hartkamp L, Strand S, Sebestyen Z et al. Redirecting alphabeta T cells against cancer cells by transfer of a broadly tumor-reactive gamma deltaT-cell receptor. Blood 2011; 118: 50-59.
21. Antoun A, Vekaria D, Salama RA, Pratt G, Jobson S, Cook M et al. The genotype of RAET1L (ULBP6), a ligand for human NKG2D (KLRK1), markedly influences the clinical outcome of allogeneic stem cell transplantation. Br J Haematol 2012; 159: 589-598.
22. Pende D, Parolini S, Pessino A, Sivori S, Augugliaro R, Morelli L et al. Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. J Exp Med 1999; 190: 1505-1516.
23. Sivori S, Vitale M, Morelli L, Sanseverino L, Augugliaro R, Bottino C et al. p46, a novel natural killer cell-specific surface molecule that mediates cell activation. J Exp Med 1997; 186: 1129-1136. (Pubitemid 27441156)
24. Vitale M, Bottino C, Sivori S, Sanseverino L, Castriconi R, Marcenaro E et al. NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. J Exp Med 1998; 187: 2065-2072. (Pubitemid 28285576)
25. Brandt CS, Baratin M, Yi EC, Kennedy J, Gao Z, Fox B et al. The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J Exp Med 2009; 206: 1495-1503.
26. Pogge von Strandmann E, Simhadri VR, von TB, Sasse S, Reiners KS, Hansen HP et al. Human leukocyte antigen-B-Associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells. Immunity 2007; 27: 965-974. (Pubitemid 350251218)
27. Bloushtain N, Qimron U, Bar-Ilan A, Hershkovitz O, Gazit R, Fima E et al. Membrane-Associated heparan sulfate proteoglycans are involved in the recognition of cellular targets by NKp30 and NKp46. J Immunol 2004; 173: 2392-2401. (Pubitemid 39063095)
28. Hershkovitz O, Jivov S, Bloushtain N, Zilka A, Landau G, Bar-Ilan A et al. Characterization of the recognition of tumor cells by the natural cytotoxicity receptor, NKp44. Biochemistry 2007; 46: 7426-7436. (Pubitemid 46986369)
29. Sanderson RD, Yang Y, Kelly T, MacLeod V, Dai Y, Theus A. Enzymatic remodeling of heparan sulfate proteoglycans within the tumor microenvironment: Growth regulation and the prospect of new cancer therapies. J Cell Biochem 2005; 96: 897-905. (Pubitemid 41688716)
30. Rosental B, Brusilovsky M, Hadad U, Oz D, Appel MY, Afergan F et al. Proliferating cell nuclear antigen is a novel inhibitory ligand for the natural cytotoxicity receptor NKp44. J Immunol 2011; 187: 5693-5702.
31. Parham P. MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol 2005; 5: 201-214. (Pubitemid 40364822)
32. Ciccone E, Pende D, Viale O, Than A, Di DC, Orengo AM et al. Involvement of HLA class I alleles in natural killer (NK) cell-specific functions: Expression of HLA-Cw3 confers selective protection from lysis by alloreactive NK clones displaying a defined specificity (specificity 2). J Exp Med 1992; 176: 963-971.
33. Maier S, Tertilt C, Chambron N, Gerauer K, Huser N, Heidecke CD et al. Inhibition of natural killer cells results in acceptance of cardiac allografts in CD28-/-mice. Nat Med 2001; 7: 557-562. (Pubitemid 32448322)
34. Eissens DN, Schaap NP, Preijers FW, Dolstra H, van CB, Schattenberg AV et al. CD3+/CD19+-depleted grafts in HLA-matched allogeneic peripheral blood stem cell transplantation lead to early NK cell cytolytic responses and reduced inhibitory activity of NKG2A. Leukemia 2010; 24: 583-591.
35. Federmann B, Hagele M, Pfeiffer M, Wirths S, Schumm M, Faul C et al. Immune reconstitution after haploidentical hematopoietic cell transplantation: Impact of reduced intensity conditioning and CD3/CD19 depleted grafts. Leukemia 2011; 25: 121-129.
36. Savani BN, Mielke S, Adams S, Uribe M, Rezvani K, Yong AS et al. Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia. Leukemia 2007; 21: 2145-2152. (Pubitemid 47423804)
37. Aversa F, Terenzi A, Tabilio A, Falzetti F, Carotti A, Ballanti S et al. Full haplotypemismatched hematopoietic stem-cell transplantation: A phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 2005; 23: 3447-3454.
38. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097-2100. (Pubitemid 34229476)
39. Long EO, Kim HS, Liu D, Peterson ME, Rajagopalan S. Controlling natural killer cell responses: Integration of signals for activation and inhibition. Annu Rev Immunol 2013; 31: 227-258.
40. Graef T, Moesta AK, Norman PJ, Abi-Rached L, Vago L, Older Aguilar AM et al. KIR2DS4 is a product of gene conversion with KIR3DL2 that introduced specificity for HLA-A.11 while diminishing avidity for HLA-C. J Exp Med 2009; 206: 2557-2572.
41. Frazier WR, Steiner N, Hou L, Dakshanamurthy S, Hurley CK. Allelic variation in KIR2DL3 generates a KIR2DL2-like receptor with increased binding to its HLA-C ligand. J Immunol 2013; 190: 6198-6208.
42. Kroger N, Zabelina T, Berger J, Duske H, Klyuchnikov E, Binder T et al. Donor KIR haplotype B improves progression-free and overall survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. Leukemia 2011; 25: 1657-1661.
43. Gasteiger G, Hemmers S, Firth MA, Le FA, Huse M, Sun JC et al. IL-2-dependent tuning of NK cell sensitivity for target cells is controlled by regulatory T cells. J Exp Med 2013; 210: 1167-1178.
44. Terme M, Ullrich E, Delahaye NF, Chaput N, Zitvogel L. Natural killer cell-directed therapies: Moving from unexpected results to successful strategies. Nat Immunol 2008; 9: 486-494. (Pubitemid 351560517)
45. Jost S, Altfeld M. Control of human viral infections by natural killer cells. Annu Rev Immunol 2013; 31: 163-194.
46. Chalupny NJ, Rein-Weston A, Dosch S, Cosman D. Down-regulation of the NKG2D ligand MICA by the human cytomegalovirus glycoprotein UL142. Biochem Biophys Res Commun 2006; 346: 175-181. (Pubitemid 43865981)
47. Welte SA, Sinzger C, Lutz SZ, Singh-Jasuja H, Sampaio KL, Eknigk U et al. Selective intracellular retention of virally induced NKG2D ligands by the human cytomegalovirus UL16 glycoprotein. Eur J Immunol 2003; 33: 194-203. (Pubitemid 36157657)
48. Arnon TI, Achdout H, Levi O, Markel G, Saleh N, Katz G et al. Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus. Nat Immunol 2005; 6: 515-523. (Pubitemid 41716765)
49. Foley B, Cooley S, Verneris MR, Pitt M, Curtsinger J, Luo X et al. Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function. Blood 2012; 119: 2665-2674.
50. Lopez-Verges S, Milush JM, Schwartz BS, Pando MJ, Jarjoura J, York VA et al. Expansion of a unique CD57(+)NKG2Chi natural killer cell subset during acute human cytomegalovirus infection. Proc Natl Acad Sci USA 2011; 108: 14725-14732.
51. Gallez-Hawkins GM, Franck AE, Li X, Thao L, Oki A, Gendzekhadze K et al. Expression of activating KIR2DS2 and KIR2DS4 genes after hematopoietic cell transplantation: Relevance to cytomegalovirus infection. Biol Blood Marrow Transplant 2011; 17: 1662-1672.
52. Zaia JA, Sun JY, Gallez-Hawkins GM, Thao L, Oki A, Lacey SF et al. The effect of single and combined activating killer immunoglobulin-like receptor genotypes on cytomegalovirus infection and immunity after hematopoietic cell transplantation. Biol Blood Marrow Transplant 2009; 15: 315-325.
53. Kroger N, Binder T, Zabelina T, Wolschke C, Schieder H, Renges H et al. Low number of donor activating killer immunoglobulin-like receptors (KIR) genes but not KIR-ligand mismatch prevents relapse and improves disease-free survival in leukemia patients after in vivo T-cell depleted unrelated stem cell transplantation. Transplantation 2006; 82: 1024-1030. (Pubitemid 44632116)
54. Marin D, Gabriel IH, Ahmad S, Foroni L, de LH, Clark R et al. KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib. Leukemia 2012; 26: 296-302.
55. Triplett BM, Horwitz EM, Iyengar R, Turner V, Holladay MS, Gan K et al. Effects of activating NK cell receptor expression and NK cell reconstitution on the outcomes of unrelated donor hematopoietic cell transplantation for hematologic malignancies. Leukemia 2009; 23: 1278-1287.
56. Verheyden S, Schots R, Duquet W, Demanet C. A defined donor activating natural killer cell receptor genotype protects against leukemic relapse after related HLA-identical hematopoietic stem cell transplantation. Leukemia 2005; 19: 1446-1451. (Pubitemid 41136340)
57. Bukowski JF, Biron CA, Welsh RM. Elevated natural killer cell-mediated cytotoxicity, plasma interferon, and tumor cell rejection in mice persistently infected with lymphocytic choriomeningitis virus. J Immunol 1983; 131: 991-996. (Pubitemid 13079054)
58. Vivier E, Ugolini S, Blaise D, Chabannon C, Brossay L. Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol 2012; 12: 239-252.
59. Hirano M, Guo P, McCurley N, Schorpp M, Das S, Boehm T et al. Evolutionary implications of a third lymphocyte lineage in lampreys. Nature 2013; 501: 435-438.
60. Bezman NA, Kim CC, Sun JC, Min-Oo G, Hendricks DW, Kamimura Y et al. Molecular definition of the identity and activation of natural killer cells. Nat Immunol 2012; 13: 1000-1009.
61. Correia DV, Lopes A, Silva-Santos B. Tumor cell recognition by gamma delta T lymphocytes: T-cell receptor vs. NK-cell receptors. Oncoimmunology 2013; 2: E22892.
62. Das H, Groh V, Kuijl C, Sugita M, Morita CT, Spies T et al. MICA engagement by human Vgamma2Vdelta2 T cells enhances their antigen-dependent effector function. Immunity 2001; 15: 83-93. (Pubitemid 32728322)
63. Rincon-Orozco B, Kunzmann V, Wrobel P, Kabelitz D, Steinle A, Herrmann T. Activation of V gamma9Vdelta2 T cells by NKG2D. J Immunol 2005; 175: 2144-2151.
64. Correia DV, Fogli M, Hudspeth K, da Silva MG, Mavilio D, Silva-Santos B. Differentiation of human peripheral blood Vdelta1+ T cells expressing the natural cytotoxicity receptor NKp30 for recognition of lymphoid leukemia cells. Blood 2011; 118: 992-1001.
65. Vantourout P, Hayday A. Six-of-The-best: Unique contributions of gamma delta T cells to immunology. Nat Rev Immunol 2013; 13: 88-100.
66. Gober HJ, Kistowska M, Angman L, Jeno P, Mori L, De LG. Human T cell receptor gamma delta cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med 2003; 197: 163-168. (Pubitemid 36152311)
67. Grunder C, van Dorp S, Hol S, Drent E, Straetemans T, Heijhuurs S et al. Gamma9 and delta2CDR3 domains regulate functional avidity of T cells harboring gamma9delta2TCRs. Blood 2012; 120: 5153-5162.
68. Bai L, Picard D, Anderson B, Chaudhary V, Luoma A, Jabri B et al. The majority of CD1d-sulfatide-specific T cells in human blood use a semiinvariant Vdelta1 TCR. Eur J Immunol 2012; 42: 2505-2510.
69. Groh V, Steinle A, Bauer S, Spies T. Recognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cells. Science 1998; 279: 1737-1740. (Pubitemid 28164472)
70. Russano AM, Bassotti G, Agea E, Bistoni O, Mazzocchi A, Morelli A et al. CD1-restricted recognition of exogenous and self-lipid antigens by duodenal gammadelta+ T lymphocytes. J Immunol 2007; 178: 3620-3626. (Pubitemid 46417629)
71. Spada FM, Grant EP, Peters PJ, Sugita M, Melian A, Leslie DS et al. Self-recognition of CD1 by gamma/delta T cells: Implications for innate immunity. J Exp Med 2000; 191: 937-948.
72. Xu B, Pizarro JC, Holmes MA, McBeth C, Groh V, Spies T et al. Crystal structure of a gammadelta T-cell receptor specific for the human MHC class I homolog MICA. Proc Natl Acad Sci USA 2011; 108: 2414-2419.
73. Leslie DS, Vincent MS, Spada FM, Das H, Sugita M, Morita CT et al. CD1-mediated gamma/delta T cell maturation of dendritic cells. J Exp Med 2002; 196: 1575-1584. (Pubitemid 36026469)
74. Brandes M, Willimann K, Moser B. Professional antigen-presentation function by human gamma delta T Cells. Science 2005; 309: 264-268. (Pubitemid 40967855)
75. Brandes M, Willimann K, Bioley G, Levy N, Eberl M, Luo M et al. Cross-presenting human gamma delta T cells induce robust CD8+ alphabeta T cell responses. Proc Natl Acad Sci U S A 2009; 106: 2307-2312.
76. Zheng J, Liu Y, Lau YL, Tu W. gamma delta-T cells: An unpolished sword in human anti-infection immunity. Cell Mol Immunol 2013; 10: 50-57.
77. Dechanet J, Merville P, Lim A, Retiere C, Pitard V, Lafarge X et al. Implication of gamma delta T cells in the human immune response to cytomegalovirus. J Clin Invest 1999; 103: 1437-1449. (Pubitemid 29535500)
78. Vermijlen D, Brouwer M, Donner C, Liesnard C, Tackoen M, Van RM et al. Human cytomegalovirus elicits fetal gamma delta T cell responses in utero. J Exp Med 2010; 207: 807-821.
79. Knight A, Madrigal AJ, Grace S, Sivakumaran J, Kottaridis P, Mackinnon S et al. The role of Vdelta2-negative gamma delta T cells during cytomegalovirus reactivation in recipients of allogeneic stem cell transplantation. Blood 2010; 116: 2164-2172.
80. Halary F, Pitard V, Dlubek D, Krzysiek R, de la SH, Merville P et al. Shared reactivity of V{delta}2(neg) {gamma}{delta} T cells against cytomegalovirus-infected cells and tumor intestinal epithelial cells. J Exp Med 2005; 201: 1567-1578.
81. Ljungman P. CMV a warrior against leukemia? Blood 2013; 122: 1101-1102.
82. Burns LJ, Weisdorf DJ, DeFor TE, Vesole DH, Repka TL, Blazar BR et al. IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: A phase I/II trial. Bone Marrow Transplant 2003; 32: 177-186. (Pubitemid 36903442)
83. Miller JS, Tessmer-Tuck J, Pierson BA, Weisdorf D, McGlave P, Blazar BR et al. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity. Biol Blood Marrow Transplant 1997; 3: 34-44. (Pubitemid 127531527)
84. Baumgarten E, Schmid H, Pohl U, Brzoska J, Linderkamp C, Siegert W et al. Low-dose natural interleukin-2 and recombinant interferon-gamma following autologous bone marrow grafts in pediatric patients with high-risk acute leukemia. Leukemia 1994; 8: 850-855.
85. Willemze R, Rodrigues CA, Labopin M, Sanz G, Michel G, Socie G et al. KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia. Leukemia 2009; 23: 492-500.
86. Farag SS, Bacigalupo A, Eapen M, Hurley C, Dupont B, Caligiuri MA et al. The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: A report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry. Biol Blood Marrow Transplant 2006; 12: 876-884. (Pubitemid 44070674)
87. Weisdorf D, Cooley S, Devine S, Fehniger TA, DiPersio J, Anasetti C et al. T cell-depleted partial matched unrelated donor transplant for advanced myeloid malignancy: KIR ligand mismatch and outcome. Biol Blood Marrow Transplant 2012; 18: 937-943.
88. Huang XJ, Zhao XY, Liu DH, Liu KY, Xu LP. Deleterious effects of KIR ligand incompatibility on clinical outcomes in haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion. Leukemia 2007; 21: 848-851.
89. Bishara A, De SD, Witt CC, Brautbar C, Christiansen FT, Or R et al. The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-Alloreactive T cells causing GVHD. Tissue Antigens 2004; 63: 204-211. (Pubitemid 38297254)
90. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005; 105: 3051-3057.
91. Venstrom JM, Pittari G, Gooley TA, Chewning JH, Spellman S, Haagenson M et al. HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. N Engl J Med 2012; 367: 805-816.
92. Fournie JJ, Sicard H, Poupot M, Bezombes C, Blanc A, Romagne F et al. What lessons can be learned from gamma delta T cell-based cancer immunotherapy trials? Cell Mol Immunol 2013; 10: 35-41.
93. Kunzmann V, Smetak M, Kimmel B, Weigang-Koehler K, Goebeler M, Birkmann J et al. Tumor-promoting versus tumor-Antagonizing roles of gamma delta T cells in cancer immunotherapy: Results from a prospective phase I/II trial. J Immunother 2012; 35: 205-213.
94. Wilhelm M, Kunzmann V, Eckstein S, Reimer P, Weissinger F, Ruediger T et al. Gamma delta T cells for immune therapy of patients with lymphoid malignancies. Blood 2003; 102: 200-206. (Pubitemid 36759655)
95. Abe Y, Muto M, Nieda M, Nakagawa Y, Nicol A, Kaneko T et al. Clinical and immunological evaluation of zoledronate-Activated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma. Exp Hematol 2009; 37: 956-968.
96. Lang JM, Kaikobad MR, Wallace M, Staab MJ, Horvath DL, Wilding G et al. Pilot trial of interleukin-2 and zoledronic acid to augment gammadelta T cells as treatment for patients with refractory renal cell carcinoma. Cancer Immunol Immunother 2011; 60: 1447-1460.
97. Moser B, Eberl M. Gammadelta T-APCs: A novel tool for immunotherapy? Cell Mol Life Sci 2011; 68: 2443-2452.
98. Kobayashi H, Tanaka Y, Yagi J, Osaka Y, Nakazawa H, Uchiyama T et al. Safety profile and anti-Tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: A pilot study. Cancer Immunol Immunother 2007; 56: 469-476. (Pubitemid 46204533)
99. Oevermann L, Lang P, Feuchtinger T, Schumm M, Teltschik HM, Schlegel P et al. Immune reconstitution and strategies for rebuilding the immune system after haploidentical stem cell transplantation. Ann N Y Acad Sci 2012; 1266: 161-170.
100. Godder KT, Henslee-Downey PJ, Mehta J, Park BS, Chiang KY, Abhyankar S et al. Long term disease-free survival in acute leukemia patients recovering with increased gamma delta T cells after partially mismatched related donor bone marrow transplantation. Bone Marrow Transplant 2007; 39: 751-757. (Pubitemid 46901973)
101. Maniar A, Zhang X, Lin W, Gastman BR, Pauza CD, Strome SE et al. Human gamma delta T lymphocytes induce robust NK cell-mediated antitumor cytotoxicity through CD137 engagement. Blood 2010; 116: 1726-1733.
102. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol 2003; 21: 685-711. (Pubitemid 37174545)
103. Gattinoni L, Powell Jr DJ, Rosenberg SA, Restifo NP. Adoptive immunotherapy for cancer: Building on success. Nat Rev Immunol 2006; 6: 383-393.
104. Ye J, Ma C, Wang F, Hsueh EC, Toth K, Huang Y et al. Specific recruitment of gamma delta regulatory T cells in human breast cancer. Cancer Res 2013; 73: 6137-6148.
105. Ye J, Ma C, Hsueh EC, Eickhoff CS, Zhang Y, Varvares MA et al. Tumor-derived gamma delta regulatory T cells suppress innate and adaptive immunity through the induction of immunosenescence. J Immunol 2013; 190: 2403-2414.
106. Cai Y, Shen X, Ding C, Qi C, Li K, Li X et al. Pivotal role of dermal IL-17-producing gamma delta T cells in skin inflammation. Immunity 2011; 35: 596-610.
107. Laggner U, Di MP, Perera GK, Hundhausen C, Lacy KE, Ali N et al. Identification of a novel proinflammatory human skin-homing Vgamma9Vdelta2 T cell subset with a potential role in psoriasis. J Immunol 2011; 187: 2783-2793.
108. Barber A, Zhang T, DeMars LR, Conejo-Garcia J, Roby KF, Sentman CL. Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer. Cancer Res 2007; 67: 5003-5008. (Pubitemid 46910210)
109. Zhang T, Barber A, Sentman CL. Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor. Cancer Res 2006; 66: 5927-5933. (Pubitemid 43927148)
110. Zhang T, Lemoi BA, Sentman CL. Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy. Blood 2005; 106: 1544-1551. (Pubitemid 41208564)
111. Chang YH, Connolly J, Shimasaki N, Mimura K, Kono K, Campana D. A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells. Cancer Res 2013; 73: 1777-1786.
112. Klingemann HG. Cellular therapy of cancer with natural killer cells-where do we stand? Cytotherapy 2013; 15: 1185-1194.
113. Arai S, Meagher R, Swearingen M, Myint H, Rich E, Martinson J et al. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: A phase I trial. Cytotherapy 2008; 10: 625-632.
114. Esser R, Muller T, Stefes D, Kloess S, Seidel D, Gillies SD et al. NK cells engineered to express a GD2-specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin. J Cell Mol Med 2012; 16: 569-581.
115. Zhang T, Sentman CL. Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells. Cancer Res 2011; 71: 2066-2076.
116. Arnon TI, Markel G, Bar-Ilan A, Hanna J, Fima E, Benchetrit F et al. Harnessing soluble NK cell killer receptors for the generation of novel cancer immune therapy. PLoS One 2008; 3: E2150.
117. Vey N, Bourhis JH, Boissel N, Bordessoule D, Prebet T, Charbonnier A et al. A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission. Blood 2012; 120: 4317-4323.
118. Marcu-Malina V, van Dorp S, Kuball J. Re-Targeting T-cells against cancer by gene-Transfer of tumor-reactive receptors. Expert Opin Biol Ther 2009; 9: 579-591.
119. Scheper W, Grunder C, Kuball J. Multifunctional gammadelta T cells and their receptors for targeted anticancer immunotherapy. Oncoimmunology 2013; 2: E23974.
120. Sadelain M, Brentjens R, Riviere I. The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol 2009; 21: 215-223.